刚刚！IPO审2过2

Core Viewpoint - The article discusses the approval of two companies for IPOs, highlighting their business operations, financial performance, and ownership structures. Group 1: Zhejiang Xinxing Tool Co., Ltd. - The company specializes in the research, production, and sales of drilling tools for hole processing, with a focus on ring and solid drilling products [5][3]. - For the year 2024, the projected revenue is 467.27 million yuan, and the net profit is expected to be 183.65 million yuan [3]. - The company has shown consistent revenue growth, with reported revenues of 391.28 million yuan, 425.25 million yuan, and 467.27 million yuan over the past three years [7]. - The controlling shareholder, Xinxing Holdings, owns 70% of the company, with the actual controllers being members of the Zhu family, who collectively hold 92.65% of the voting rights [6][5]. Group 2: Shanghai Baiying Biotechnology Co., Ltd. - The company focuses on antibody and protein expression, as well as antibody discovery and optimization, operating as a Contract Research Organization (CRO) [11]. - The projected revenue for 2024 is 402.39 million yuan, with a net profit of 123.83 million yuan [4][13]. - The company has experienced revenue growth, with reported revenues of 260.44 million yuan, 338.39 million yuan, and 402.39 million yuan over the past three years [13]. - The controlling shareholder, Cha Changchun, holds a total of 50.02% of the company's shares, ensuring significant influence over corporate decisions [12].